Négrier, S <br/><br/>
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  Jul 2014 
 - 1766-1771 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2014.03.012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease-Free Survival<br/>Endpoint Determination<br/>Humans<br/>Indoles--therapeutic use<br/>Interferon-alpha--therapeutic use<br/>Kaplan-Meier Estimate<br/>Kidney Neoplasms--drug therapy<br/>Multicenter Studies as Topic<br/>Pyrroles--therapeutic use<br/>Randomized Controlled Trials as Topic<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Sunitinib<br/>Time Factors<br/>Treatment Outcome